U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C3H6O3
Molecular Weight 90.0779
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LACTIC ACID, L-

SMILES

C[C@H](O)C(O)=O

InChI

InChIKey=JVTAAEKCZFNVCJ-REOHCLBHSA-N
InChI=1S/C3H6O3/c1-2(4)3(5)6/h2,4H,1H3,(H,5,6)/t2-/m0/s1

HIDE SMILES / InChI

Molecular Formula C3H6O3
Molecular Weight 90.0779
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Lactic Acid, L- (L-lactic acid, L-lactate) is the levorotatory isomer of lactic acid, the biologically active isoform in humans. Lactic acid or lactate is produced during fermentation from pyruvate by lactate dehydrogenase. Lactate dehydrogenase is isomer-specific so that production and metabolism of D-lactate require D-LDH and L-lactate requires L-LDH. Mammalian cells only contain L-LDH so that in humans the lactate produced is almost exclusively L-lactate. Carbohydrate-fermenting bacterial species (e.g. lactobacillus spp) have by contrast both enzymes and therefore the capacity to produce both D-lactate and L-lactate. L-lactic acid is the primary agonist of hydroxycarboxylic acid receptor 1 (HCA1), which is a Gi/o-coupled G protein-coupled receptor (GPCR). Poly-L-lactic acid is an absorbable, semi-permanent, injectable implant that can be used to restore volume and stimulate collagen formation gradually. It is FDA-approved for the correction of facial fat loss associated with antiretroviral therapy-induced lipoatrophy in HIV patients. It is FDA-approved for use in immunocompetent people for the correction of nasolabial fold deficiencies and other facial wrinkles. It has been used off-label to enhance the cheeks, hands, neck, thighs, gluteal enhancement and chest wall deformities, such as pectus excavatum or thoracic deformities secondary to surgical procedures.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q9BXC0
Gene ID: 27198.0
Gene Symbol: HCAR1
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
PRISMASOL

Approved Use

PRISMASOL solution is indicated as a replacement solution in Continuous Renal Replacement Therapy (CRRT) and in case of drug poisoning when CRRT is used to remove dialyzable substances.

Launch Date

1.16164801E12
PubMed

PubMed

TitleDatePubMed
Lactate- and isoproterenol-induced panic attacks in panic disorder patients and controls.
1988 Feb
Cloning of a lactate dehydrogenase gene from Clostridium acetobutylicum B643 and expression in Escherichia coli.
1990 Dec
Physiology and pathophysiology of organic acids in cerebrospinal fluid.
1993
Paraquat-induced renal injury studied by 1H nuclear magnetic resonance spectroscopy of urine.
1998 Jun
L-lactic acid as a mosquito (Diptera: Culicidae) repellent on human and mouse skin.
2001 Jan
1H and (13)C NMR spectroscopic analysis of human saliva.
2002 Jun
Role of GPR81 in lactate-mediated reduction of adipose lipolysis.
2008 Dec 19
Design of a "new motif" with beta-amino acids and alpha-aminoxy acids: synthesis of hybrid peptides with 12/10-helix.
2008 May 16
Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor, GPR81.
2009 Jan 30
Studies on the biodegradation of fosfomycin: growth of Rhizobium huakuii PMY1 on possible intermediates synthesised chemically.
2009 May 7
Patents

Sample Use Guides

Facial fat loss (lipoatrophy) Sculptra (Poly-L-lactic acid): Intradermal or SubQ: ~0.05-0.2 mL per individual injection depending on technique used; ~20 injections may be needed per cheek. Treatment should be individualized. Separate treatments by ≥2 weeks. Typical course involves 3-6 treatments. Supplemental injections may be needed. Do not overfill contour deficiency. For patients with severe facial fat loss, the average treatment requires ~1 vial per cheek area per treatment.
Route of Administration: Other
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:37:57 UTC 2023
Edited
by admin
on Wed Jul 05 22:37:57 UTC 2023
Record UNII
F9S9FFU82N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LACTIC ACID, L-
II  
Common Name English
L-LACTIC ACID
MI  
Common Name English
L- LACTIC ACID (+)
Common Name English
(S)-(+)-LACTIC ACID
Systematic Name English
L(+)-LACTIC ACID
Common Name English
(S)-LACTIC ACID [EP MONOGRAPH]
Common Name English
SARCOLACTICUM ACIDUM [HPUS]
Common Name English
(2S)-2-HYDROXYPROPANOIC ACID
Systematic Name English
LACTIC ACID, L- [II]
Common Name English
L-LACTIC ACID [MI]
Common Name English
(+)-LACTIC ACID
Systematic Name English
(S)-LACTIC ACID
EP  
Systematic Name English
Sarcolactic acid [WHO-DD]
Common Name English
SARCOLACTICUM ACIDUM
HPUS  
Common Name English
DEXTROROTATORY LACTIC ACID
Common Name English
SARCOLACTIC ACID
WHO-DD  
Common Name English
PARALACTIC ACID
Common Name English
L-(+)-LACTIC ACID
Common Name English
L-LACTIC ACID [JAN]
Common Name English
Classification Tree Code System Code
EPA PESTICIDE CODE 128929
Created by admin on Wed Jul 05 22:37:57 UTC 2023 , Edited by admin on Wed Jul 05 22:37:57 UTC 2023
Code System Code Type Description
RS_ITEM_NUM
1356734
Created by admin on Wed Jul 05 22:37:57 UTC 2023 , Edited by admin on Wed Jul 05 22:37:57 UTC 2023
PRIMARY
EVMPD
SUB11686MIG
Created by admin on Wed Jul 05 22:37:57 UTC 2023 , Edited by admin on Wed Jul 05 22:37:57 UTC 2023
PRIMARY
FDA UNII
F9S9FFU82N
Created by admin on Wed Jul 05 22:37:57 UTC 2023 , Edited by admin on Wed Jul 05 22:37:57 UTC 2023
PRIMARY
EVMPD
SUB35198
Created by admin on Wed Jul 05 22:37:57 UTC 2023 , Edited by admin on Wed Jul 05 22:37:57 UTC 2023
PRIMARY
RXCUI
2462499
Created by admin on Wed Jul 05 22:37:57 UTC 2023 , Edited by admin on Wed Jul 05 22:37:57 UTC 2023
PRIMARY
NCI_THESAURUS
C61808
Created by admin on Wed Jul 05 22:37:57 UTC 2023 , Edited by admin on Wed Jul 05 22:37:57 UTC 2023
PRIMARY
DAILYMED
F9S9FFU82N
Created by admin on Wed Jul 05 22:37:57 UTC 2023 , Edited by admin on Wed Jul 05 22:37:57 UTC 2023
PRIMARY
EPA CompTox
DTXSID6034689
Created by admin on Wed Jul 05 22:37:57 UTC 2023 , Edited by admin on Wed Jul 05 22:37:57 UTC 2023
PRIMARY
MERCK INDEX
M6655
Created by admin on Wed Jul 05 22:37:57 UTC 2023 , Edited by admin on Wed Jul 05 22:37:57 UTC 2023
PRIMARY Merck Index
CHEBI
422
Created by admin on Wed Jul 05 22:37:57 UTC 2023 , Edited by admin on Wed Jul 05 22:37:57 UTC 2023
PRIMARY
DRUG BANK
DB14475
Created by admin on Wed Jul 05 22:37:57 UTC 2023 , Edited by admin on Wed Jul 05 22:37:57 UTC 2023
PRIMARY
PUBCHEM
107689
Created by admin on Wed Jul 05 22:37:57 UTC 2023 , Edited by admin on Wed Jul 05 22:37:57 UTC 2023
PRIMARY
SMS_ID
100000076647
Created by admin on Wed Jul 05 22:37:57 UTC 2023 , Edited by admin on Wed Jul 05 22:37:57 UTC 2023
PRIMARY
CAS
79-33-4
Created by admin on Wed Jul 05 22:37:57 UTC 2023 , Edited by admin on Wed Jul 05 22:37:57 UTC 2023
PRIMARY
ECHA (EC/EINECS)
201-196-2
Created by admin on Wed Jul 05 22:37:57 UTC 2023 , Edited by admin on Wed Jul 05 22:37:57 UTC 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY